AventuSoft
AventuSoft is a privately held Boca Raton healthcare AI company that builds HEMOTAG, a non-invasive cloud-connected cardiac diagnostic device, alongside the CarePear tele-care platform and Trialogy decentralized clinical trials platform, selling to hospitals and clinics.
- Company typePrivate
- Founded2014
- HeadquartersBoca Raton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AventuSoft does
AventuSoft LLC is a privately held Boca Raton, Florida healthcare technology company founded in 2014 to commercialize signal-detection technology originally developed for the Department of Defense. The company operates a portfolio of three AI-enabled products. Its flagship, HEMOTAG CPAS, is a non-invasive, rechargeable, reusable, cloud-connected cardiac diagnostic system that uses everyday smartphones and proprietary sensors to assess left ventricular systolic function, diastolic function, left ventricular pressure, congestion, and lead-1 ECG vital signs without requiring a skilled operator; sensor data is sent to a HIPAA-compliant cloud, analyzed with machine-learning algorithms, and delivered to the care team as an electronic patient report within minutes. CarePear is a tele-care platform that connects patients with US-based sub-specialists across endocrinology, rheumatology, hematology, oncology, pulmonology, and pediatric specialties via secure video consultation, with consent, medical-history, and payment functionality built in. Trialogy is an AI-driven decentralized clinical trials platform positioned for the life sciences market.
The company generates revenue through a mix of hardware and software sales of HEMOTAG to hospitals and clinics, subscription and usage access to CarePear, clinical study services delivered to health system partners such as Cleveland Clinic Florida and HCA-JFK Hospital, and non-dilutive research funding from NIH institutes (NHLBI, NIDDK, NIBIB, NIMHD), NSF, and DARPA via the SBIR/STTR programs. Go-to-market combines direct enterprise engagement with hospitals, OB/GYN clinics, primary care offices, emergency medical services, and community clinics, alongside US Commercial Service-supported international expansion into Costa Rica and Panama. Key customers and clinical partners include Cleveland Clinic Florida, HCA-JFK Hospital, the University of Miami Miller School of Medicine at JFK Campus, UF Health, Baylor Scott & White Health, the Caja Costarricense de Seguro Social, and multiple private Central American hospitals.
AventuSoft firmographics
Firmographics- Name
- AventuSoft
- Legal name
- Aventusoft LLC
- Website
- https://aventusoft.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AventuSoft is a privately held Boca Raton healthcare AI company that builds HEMOTAG, a non-invasive cloud-connected cardiac diagnostic device, alongside the CarePear tele-care platform and Trialogy decentralized clinical trials platform, selling to hospitals and clinics.
- Ownership category
- akta.pro rank
AventuSoft industry classification
Industry- Product category
- Cardiac Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where AventuSoft is headquartered
LocationHeadquarters
- HQ city
- Boca Raton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AventuSoft business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- HEMOTAG Device Sales: Sale of HEMOTAG cardiac diagnostic hardware devices and associated software platform to healthcare providers and institutions
- CarePear Tele-Care Platform: Subscription or usage-based access to tele-care platform enabling video consultations with US-based specialist physicians
- NIH/DARPA Research Grants: Government funding through SBIR/STTR grants from NIH institutes (NHLBI, NIDDK, NIBIB, NIMHD) and DARPA for product development and clinical trials
- Clinical Trial Services: Revenue from clinical study partnerships with major hospital systems (Cleveland Clinic, JFK Medical Center) for product validation and expanded indications
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise Healthcare Pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
AventuSoft product offering
Product offeringCore offering
AventuSoft develops and sells the HEMOTAG non-invasive cardiac diagnostic hardware device paired with a HIPAA-compliant cloud AI/ML analytics platform that assesses left ventricular systolic/diastolic function, left ventricular pressure, congestion, and lead-1 ECG vital signs. The company also operates CarePear, a tele-care platform connecting patients to US-based sub-specialists, and Trialogy, an AI-driven decentralized clinical trials platform.
Product overview
AventuSoft is a healthcare technology firm offering a portfolio of three distinct products focused on cardiac health and telehealth: Hemotag (non-invasive cardiac diagnostics device and cloud AI platform), CarePear (tele-care platform connecting patients with US-based specialists), and Trialogy (AI-driven decentralized clinical trials platform). Hemotag serves as the core cardiac monitoring solution with AI-powered diagnostics, CarePear extends specialist access through telehealth consultations, and Trialogy supports clinical research. All products leverage cloud connectivity and AI/ML capabilities for remote patient monitoring and care delivery.
Differentiator
Problem solved
Functional benefit
Brands
- Hemotag: Device and digital health AI platform for non-invasive cardiac diagnostics and remote monitoring, providing hemodynamic assessment of cardiac pressure and function.
- CarePear
- Trialogy
Products and services
- HEMOTAG CPAS Cardiac Diagnostic System Non-invasive, rechargeable, reusable, secure cloud-connected device and digital health platform for cardiac diagnostics and remote monitoring. Provides assessment of left ventricular systolic function, diastolic function, left ventricular pressure, congestion, and lead-1 ECG-based vital-sign assessment. Sold to healthcare providers and institutions including hospitals, OB/GYN clinics, primary care offices, and emergency medical services.
- CarePear Tele-Care Platform AI health platform enabling patients and physicians to access US-based sub-specialists via video consultation with bank-grade HIPAA-compliant security. Covers Endocrinology, Rheumatology, Hematology, Oncology, Pulmonology, and Pediatric specialties. Allows patients to sign intake/consent forms, update medical history, and upload medical records. Accessed via desktop, tablet, or smartphone.
- Trialogy AI-driven decentralized clinical trials platform enabling the future of clinical research by connecting life science with AI.
Quantifiable outcome
- 146% revenue growth over two-year period (2019-2021)
- +3 more outcomes
Companies that use AventuSoft
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
AventuSoft technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
AventuSoft partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Cleveland Clinic FloridacoreClinical trial partner for HEMOTAG CPAS congestive heart failure studies. Studies led by Advanced Heart Disease and Transplant Cardiologist Jaime Hernandez-Montfort, MD and Robert Cubeddu, MD from Cleveland Clinic Florida. Tier 1 hospital research partner.
- HCA-JFK HospitalcoreClinical trial site for HEMOTAG CPAS studies encompassing clinical and health economic outcome data from 420 patients. Led by Robert Chait, MD and Waqas Ghumman, MD.
- University of Miami Miller School of Medicine at JFK CampuscoreAcademic medical center partnership providing cardiology fellowship program and clinical trial oversight. Steven Borzak, MD serves as Associate Program Director.
- Florida Atlantic University (FAU) Research ParkminorIn 2018, Aventusoft was selected by Research Park at FAU to receive funding for GrowFL's strategic research economic gardening initiative. Aventusoft is a member of the Florida Atlantic University Health Network.
- U.S. Commercial Service / International Trade AdministrationcoreTrade promotion arm of U.S. Department of Commerce assisting U.S. firms in selling products around the world. Aventusoft participated as Certified Trade Mission and Gold Key service member for Central American market entry.
- UF HealthminorAcademic health system partner for clinical studies. Ali Ataya, MD serves as Cardiologist and PI Clinical Studies at UF Health.
- Baylor Scott & White HealthminorHealthcare system partner for clinical studies. Jaime Hernandez-Monfort, MD serves as Advanced Heart Failure Cardiologist and PI Clinical Studies.
- Costa Rica Healthcare InstitutionsminorCarePear trade mission partners including Caja Costarricense de Seguro Social (CCSS), Camara Costarricense de la Salud, Hospital Clínica Bíblica, Hospital CIMA, Hospital Metropolitano for connecting patients with US-based specialists.
- Panama Healthcare InstitutionsminorCarePear trade mission partners including Asociación Panameña de Cardiología, Asociación Panameña de Medicina Familiar, Clínica Panamá, Punta Pacífica Hospital for tele-care platform distribution.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
AventuSoft competitors and assessment
Company assessmentDirect peers
- Caretaker Medical: Develops non-invasive, continuous hemodynamic monitoring devices (VitalStream) that measure blood pressure, cardiac output, and other hemodynamic parameters without catheters. Directly comparable to HEMOTAG's non-invasive hemodynamic assessment approach.
- Biobeat: Offers wearable, AI-powered remote patient monitoring devices capturing continuous vital signs and hemodynamic parameters including blood pressure, stroke volume, and cardiac output. Competes with HEMOTAG in non-invasive AI-driven cardiac monitoring.
- HeartFlow: Provides non-invasive, AI-driven cardiac diagnostic analysis (FFR-CT) that avoids invasive catheterization. Directly comparable mission to HEMOTAG of replacing invasive cardiac diagnostics with non-invasive AI-based assessment.
- iRhythm Technologies: AI-powered ambulatory cardiac monitoring (Zio patch) for arrhythmia detection, with cloud-based analytics. Comparable model of combining a wearable cardiac sensor with cloud AI for diagnostic insights.
Broad incumbents
- Edwards Lifesciences: Global leader in hemodynamic monitoring (Swan-Ganz catheters) and structural heart disease. Represents the established standard-of-care invasive approach that non-invasive technologies like HEMOTAG aim to displace.
- Baxter International (Starling SV): Markets Starling SV, a non-invasive hemodynamic monitoring system using bioreactance. Closest large-cap analog to HEMOTAG's non-invasive cardiac output/pressure measurement value proposition.
- Philips (Cardiac Monitoring): Major medical device incumbent offering cardiac monitoring, ECG, and remote patient monitoring solutions across hospital and ambulatory settings. Represents the established competition in cardiac diagnostics.
- GE HealthCare: Large incumbent in cardiac diagnostics, patient monitoring, and AI-enabled healthcare analytics. Represents the broader competitive and potential partnership/buyer landscape for HEMOTAG and the AI platform.
Emerging players
- Teladoc Health: Large-scale telehealth platform connecting patients to physicians across specialties. Comparable to AventuSoft's CarePear platform in offering specialist access via remote consultations.
- Medable: Decentralized clinical trials platform enabling remote patient participation in studies. Directly comparable to AventuSoft's Trialogy product category.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
AventuSoft social profiles
Digital presenceAventuSoft compliance and trust
Trust signalCompliance2 records
AventuSoft financial estimates
Financial estimateRevenue estimate
Valuation estimate
AventuSoft leadership team
Management profileNumber of profiles
Profiles7 records
AventuSoft subsidiaries and ownership
Company hierarchySubsidiaries2 records
AventuSoft funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AventuSoft M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AventuSoft
What does AventuSoft do?
AventuSoft develops and sells the HEMOTAG non-invasive cardiac diagnostic hardware device paired with a HIPAA-compliant cloud AI/ML analytics platform that assesses left ventricular systolic/diastolic function, left ventricular pressure, congestion, and lead-1 ECG vital signs. The company also operates CarePear, a tele-care platform connecting patients to US-based sub-specialists, and Trialogy, an AI-driven decentralized clinical trials platform.
Is AventuSoft a public or private company?
AventuSoft is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AventuSoft founded?
AventuSoft was founded in 2014. It employs 11 to 50 people.
Where is AventuSoft based?
AventuSoft is headquartered in Boca Raton, United States, in the North America region.
How does AventuSoft make money?
Four revenue lines are on record. HEMOTAG Device Sales are the primary driver. The others are carePear Tele-Care Platform, NIH/DARPA Research Grants and clinical Trial Services.
Who are AventuSoft's main competitors?
Direct peers on record are Caretaker Medical, Biobeat, HeartFlow and iRhythm Technologies. Broad incumbents are Edwards Lifesciences, Baxter International (Starling SV), Philips (Cardiac Monitoring) and GE HealthCare. Emerging players are Teladoc Health and Medable.
Does AventuSoft have an API?
No public API is recorded for AventuSoft.
What industry is AventuSoft in?
AventuSoft's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.